Evinature Company Profile

Background

Evinature, established in 2021, is a digital healthcare platform dedicated to providing evidence-based, natural remedies for gastrointestinal conditions, particularly Inflammatory Bowel Disease (IBD). The company's mission is to bridge the gap between modern and traditional medicine, offering patients safe, effective, and accessible care. Evinature's flagship product, the CurQD® Protocol, is a clinically validated, plant-based therapy developed through extensive research at Sheba Medical Center, one of Newsweek's top 10 hospitals globally.

Key Strategic Focus

Evinature's strategic focus centers on:

• Integrative Therapies: Combining modern medical practices with traditional herbal remedies to develop treatments for IBD and related gastrointestinal disorders.

• Clinical Validation: Ensuring all products undergo rigorous clinical trials to meet high scientific standards.

• Digital Accessibility: Utilizing an online platform to provide personalized treatment plans, making therapies accessible to a global patient base.

• Global Expansion: Establishing partnerships to distribute products internationally, enhancing treatment accessibility.

Financials and Funding

In December 2022, Evinature secured $2 million in a seed funding round. The investment was led by Ratio Technologies (Israel) and angel investor Shay Livnat. The capital is intended to support product development, clinical research, and international market expansion.

Pipeline Development

Evinature's primary product, the CurQD® Protocol, is a combination of curcumin and Qing Dai, designed for treating moderate to severe ulcerative colitis. Clinical trials have demonstrated:

• 85.7% Clinical Response Rate: Patients experienced significant symptom improvement.

• 50% Clinical Remission Rate: Half of the participants achieved remission.

These results underscore the protocol's efficacy and potential as a mainstream treatment option.

Technological Platform and Innovation

Evinature distinguishes itself through:

• Proprietary Protocols: Development of unique, evidence-based treatment protocols like CurQD®.

• Clinical Research: Conducting placebo-controlled trials to validate product efficacy.

• Digital Health Platform: Offering personalized treatment plans and ongoing support through an online interface, enhancing patient engagement and adherence.

Leadership Team

• Apan Amos Damri: Co-Founder & Chief Executive Officer. Leads strategic direction and oversees company operations.

• Nir Salomon: Co-Founder & Head of Research and Development. An integrative medical expert, instrumental in developing the CurQD® Protocol.

• Professor Shomron Ben-Horin, MD: Co-Founder & Chief Medical Officer. A leading gastroenterologist, contributing extensive clinical expertise to product development.

Competitor Profile

Market Insights and Dynamics

The global IBD treatment market is experiencing significant growth due to rising prevalence rates and increased demand for effective therapies. Patients are increasingly seeking integrative and natural treatment options, creating opportunities for companies like Evinature.

Competitor Analysis

Key competitors include:

• Treasure of the East: Offers premium herbal extract granules used in traditional Chinese medicine, focusing on quality and sustainability.

• Nature's Own: Provides a range of natural health products, including supplements for digestive health.

• VSL#3: Specializes in high-potency probiotic formulations aimed at managing gastrointestinal disorders.

These companies emphasize natural and evidence-based approaches, similar to Evinature's strategy.

Strategic Collaborations and Partnerships

In August 2023, Evinature partnered with Adacyte Therapeutics, granting them exclusive distribution rights for the CurQD® Protocol in Spain, with plans to expand to Portugal. This collaboration aims to enhance treatment accessibility for IBD patients in these regions.

Operational Insights

Evinature's competitive advantages include:

• Evidence-Based Products: Commitment to clinical validation ensures product credibility.

• Digital Accessibility: Online platform facilitates personalized care and broad reach.

• Strategic Partnerships: Collaborations with established companies enhance market penetration and distribution capabilities.

Strategic Opportunities and Future Directions

Evinature plans to:

• Expand Internationally: Build on the partnership with Adacyte Therapeutics to enter additional European markets.

• Develop New Products: Continue research to create additional evidence-based natural therapies for various gastrointestinal conditions.

• Enhance Digital Platform: Invest in technology to improve user experience and patient engagement.

Contact Information

• Website: evinature.com

• Social Media: Facebook, Instagram, LinkedIn

Note: Specific contact details such as address, phone number, and email are not provided in this profile.